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Abstract

Background: Substantial evidence from human post-mortem and genetic studies has linked the neurotrophic
factor neuregulin 1 (NRG1) to the pathophysiology of schizophrenia. Genetic animal models and in vitro
experiments have suggested that altered NRG1 signaling, rather than protein changes, contributes to the
symptomatology of schizophrenia. However, little is known about the effect of NRG1 on schizophreniarelevant behavior and neurotransmission (particularly GABAergic and glutamatergic) in adult animals.
Method: To address this question, we treated adult mice with the extracellular signaling domain of NRG1 and
assessed spontaneous locomotor activity and acoustic startle response, as well as extracellular GABA,
glutamate, and glycine levels in the prefrontal cortex and hippocampus via microdialysis. Furthermore, we
asked whether the effect of NRG1 would differ under schizophrenia-relevant impairments in mice and
therefore co-treated mice with NRG1 and phencyclidine (PCP) (3mg/kg). Results: Acute intraventricularlyor systemically-injected NRG1 did not affect spontaneous behavior, but prevented PCP induced
hyperlocomotion and deficits of prepulse inhibition. NRG1 retrodialysis (10nM) reduced extracellular
glutamate and glycine levels in the prefrontal cortex and hippocampus, and prevented PCP-induced increase
in extracellular GABA levels in the hippocampus. Conclusion: With these results, we provide the first
compelling in vivo evidence for the involvement of NRG1 signaling in schizophrenia-relevant behavior and
neurotransmission in the adult nervous system, which highlight its treatment potential. Furthermore, the
ability of NRG1 treatment to alter GABA, glutamate, and glycine levels in the presence of PCP also suggests
that NRG1 signaling has the potential to alter disrupted neurotransmission in patients with schizophrenia.
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Abstract
Background: Substantial evidence from human post-mortem and genetic studies has linked the neurotrophic factor
neuregulin 1 (NRG1) to the pathophysiology of schizophrenia. Genetic animal models and in vitro experiments have suggested
that altered NRG1 signaling, rather than protein changes, contributes to the symptomatology of schizophrenia. However, little
is known about the effect of NRG1 on schizophrenia-relevant behavior and neurotransmission (particularly GABAergic and
glutamatergic) in adult animals.
Method: To address this question, we treated adult mice with the extracellular signaling domain of NRG1 and assessed
spontaneous locomotor activity and acoustic startle response, as well as extracellular GABA, glutamate, and glycine levels in
the prefrontal cortex and hippocampus via microdialysis. Furthermore, we asked whether the effect of NRG1 would differ under
schizophrenia-relevant impairments in mice and therefore co-treated mice with NRG1 and phencyclidine (PCP) (3 mg/kg).
Results: Acute intraventricularly- or systemically-injected NRG1 did not affect spontaneous behavior, but prevented PCP
induced hyperlocomotion and deficits of prepulse inhibition. NRG1 retrodialysis (10 nM) reduced extracellular glutamate and
glycine levels in the prefrontal cortex and hippocampus, and prevented PCP-induced increase in extracellular GABA levels in
the hippocampus.
Conclusion: With these results, we provide the first compelling in vivo evidence for the involvement of NRG1 signaling
in schizophrenia-relevant behavior and neurotransmission in the adult nervous system, which highlight its treatment
potential. Furthermore, the ability of NRG1 treatment to alter GABA, glutamate, and glycine levels in the presence
of PCP also suggests that NRG1 signaling has the potential to alter disrupted neurotransmission in patients with
schizophrenia.
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Introduction
Substantial evidence from human and animal studies has linked
the neurotrophic factor neuregulin 1 (NRG1) to the pathophysiology of schizophrenia (Stefansson et al., 2002; Petryshen et al.,
2005; Buonanno, 2010; Agim et al., 2013). The majority of identified polymorphisms are located in the non-coding region of the
NRG1 gene. This suggests a change in NRG1 isoform expression
levels, rather than a change in the amino acid sequence of the
proteins themselves (Buonanno, 2010). Post-mortem analyses
of NRG1 mRNA and protein expression levels in the prefrontal cortex (PFC) and hippocampus have reported increased,
decreased, and unchanged levels of NRG1 isoforms and altered
isoform type ratios in patients with schizophrenia (Hashimoto
et al., 2004; Hahn et al., 2006; Law et al., 2006; Bertram et al.,
2007; Chong et al., 2008; Barakat et al., 2010). While differences
in NRG1 expression vary between patients, the findings suggest
altered NRG1 signaling in the schizophrenia pathophysiology.
Genetic animal models with previously identified or novel
mutations in the NRG1 gene have been developed (Lu et al., 2011).
These modifications resulted in schizophrenia-relevant behavioral (e.g. hyperlocomotion and sensorimotor gating impairments)
and neurochemical (e.g. altered glutamate and γ-aminobutyric
acid [GABA] neurotransmission) impairments (Stefansson et al.,
2002; Karl et al., 2007; Kato et al., 2010; Wen et al., 2010; Shamir
et al., 2012; Luo et al., 2013; Mitchell et al., 2013; Yin et al., 2013).
Furthermore, differences in brain NRG1 expression have been
identified in several schizophrenia-relevant rodent models (Du
Bois et al., 2012; Radonjić et al., 2013; Rhein et al., 2013; Swerdlow
et al., 2013). The rodent studies indicate that changes to NRG1
signaling have functional consequences relevant to the schizophrenia pathophysiology.
The neurotrophic factor NRG1 is expressed throughout the
nervous system, with expression levels strongly influenced by
neuronal activity (Liu et al., 2011). Recent research has identified
an involvement of NRG1 signaling in neurotransmission of the
adult brain, such as GABA release (Woo et al., 2007; Wen et al.,
2010), GABA receptor currents (Woo et al., 2007; Chen et al., 2010),
and receptor expression levels (Okada and Corfas, 2004; Allison
et al., 2011; Mitchell et al., 2013). Furthermore, glutamate release
(Gu et al., 2005; Pitcher et al., 2011; Yin et al., 2013) and N-MethylD-aspartic acid (NMDA) receptor functions are also reportedly
influenced by NRG1 signaling (Gu et al., 2005; Bjarnadottir et al.,
2007; Bennett, 2009; Pitcher et al., 2011). The neurotransmission
effects of NRG1 appear to be primarily mediated through the epidermal growth factor receptor tyrosine kinase ERBB4, but might
also involve other epidermal growth factor receptor tyrosine
kinase (ERBB) receptor isoforms (Iwakura and Nawa, 2013; Mei
and Nave, 2014). ERBB4 is expressed on GABAergic interneurons and glia in the PFC and hippocampus (Gerecke et al., 2001;
Longart et al., 2007; Calvo et al., 2010; Fazzari et al., 2010; Neddens
et al., 2011), with other ERBB isoforms expressed throughout the central and peripheral nervous system (Iwakura and
Nawa, 2013). The in vitro studies suggest that NRG1 signaling is
involved in neurotransmission relevant to schizophrenia pathophysiology, potentially contributing to differences observed in
the GABAergic and glutamatergic neurotransmitter systems in
patients (Moghaddam and Javitt, 2012; Inan et al., 2013). However,
the consequence of altered NRG1 signaling on schizophrenia-relevant neurotransmission differences has not yet been explored.
Genetic animal models and in vitro studies indicate a role for
NRG1 signaling in schizophrenia, but how NRG1 affects schizophrenia-relevant behavior and neurotransmission (particularly
GABAergic and glutamatergic) in adult animals is unknown.
To address this question, we treated adult mice with the

extracellular signaling domain of NRG1 and assessed spontaneous behavior (locomotor activity and acoustic startle response),
as well as extracellular neurotransmitter levels (GABA, glutamate, and glycine). Furthermore, we asked whether the effect of
NRG1 would differ under schizophrenia-relevant impairments
in mice, since differences in NRG1 expression levels have been
found in patients with schizophrenia. We therefore co-treated
mice with NRG1 and phencyclidine (PCP), a commonly used substance for modeling schizophrenia-like behavioral and neurotransmission impairments in rodents (Adell et al., 2012; Javitt
et al., 2012; Moghaddam and Krystal, 2012; Pratt et al., 2012).
With our experiments we show that NRG1 treatment prevented
PCP-induced impairments, which gives rise to the idea of NRG1
having antipsychotic-like properties.

Methods
Animals
Ten-week-old male C57BL6j mice were purchased from Animal
Resource Centre for locomotor activity and microdialysis
experiments and Australian BioResources for sensorimotor
gating experiments. Animals were group-housed in open-lid
cages with minimal enrichment (M1 polypropylene cages; Able
Scientific) and maintained on a 12 h light/dark cycle (light on
at 0600 hours) with food and water available ad libitum in the
animal facilities of the University of Wollongong (open field
and microdialysis experiments) and Neuroscience Research
Australia (sensorimotor gating experiments). All research and
animal care procedures were approved by either the Animal
Ethics Committee of the University of Wollongong (AE10/07 and
AE11/18) or University of New South Wales (4149794) and were
in agreement with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes. Mice were acclimatized for at least one week prior to experiments. For behavioral
studies, testing order was pseudo-randomized to account for
diurnal variations. For microdialysis studies, testing order was
constant to allow the comparison of molecular responses.

Drugs
All compounds were obtained from Sigma except where specified otherwise. Drugs were freshly prepared on each treatment
day. Recombinant human NRG1 (NRG1-β1/HRG1-β1 EGF domain
CF; R&D Systems) and PCP were dissolved in either artificial cerebrospinal fluid (ACSF, 119 mM NaCl; 2.5 mM CaCl2; 2.5 mM KCl;
1.3 mM MgSO4; 1 mM NaH2PO4; 26.2 mM NaHCO3; 11 mM glucose,
7.4 pH, 290 mOsm/kg) for i.c.v. injections and retrodialysis or
in 0.9% NaCl (vehicle) for i.p. injections. For behavioral testing,
each mouse received no more than three treatments with an
inter-test interval of one week.

Open Field Behavior
The receptors for NRG1 are expressed throughout the nervous system and have also been found on muscle tissue (Zhu
et al., 1995; Bersell et al., 2009; Wadugu and Kühn, 2012).
Peripheral NRG1 treatment might therefore directly affect muscle cells, masking possible central nervous system responses.
Independent open field experiments with i.c.v. and i.p. NRG1
administration were therefore performed.

Intracerebroventricular Cannula Implantation
Mice destined for i.c.v. treatment underwent surgical implantation of an i.c.v. cannula one week prior to experiments.
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Animals were anaesthetized with an inhalation 1.5% isoflurane
(Delvet)/98.5% oxygen mix. Using a stereotactic frame (Kopf
Instruments), a 21 G guide cannula was implanted into the brain,
targeting the right lateral ventricle (Bregma -0.25 mm rostral,
-1 mm medial, -1.5 mm from top of skull; Paxinos and Franklin,
2001). The guide cannula was fixed to the skull with anchor
screws (2 mm, Microbiotech) and dental acrylic (Ketac Cem,
Halas Dental Limited). All animals were injected with 0.1 ml of a
depot-antibiotic substance (Medicam, Boehriner Ingelheim) and
additionally received it in their drinking water (0.1%) for three
days following surgery. Dummy cannula (28 G), were inserted
into the guide to keep it clean and prevent occlusion. Following
surgery, mice were individually housed and their recovery was
monitored daily until the behavioral experiments commenced.

Locomotion After Treatment
Mice were habituated to a round open field arena (40 cm diameter)
for 30 min before i.p. and/or i.c.v. injections, and re-exposed to the
open field for 30 min thereafter. For the i.p. experiments, all animals (n = 8/group) received an i.p. injection of NRG1 (5, 25, or 50 µg/
kg), PCP (3 mg/kg), PCP + NRG1 (5, 25, or 50 µg/kg), or vehicle. For
the i.c.v. experiments, all animals (n = 6–8/group) received an i.c.v.
injection of NRG1 (3, 30, or 300 ng/kg) or ACSF and simultaneously
an i.p. injection of PCP (3 mg/kg) or vehicle. NRG1 concentrations
were selected below reported sedative levels (Snodgrass-Belt et al.,
2005). Distance traveled was recorded before and after injections
using the EthoVision tracking system (Noldus). Activity data were
collected in 5 min intervals, with individual post-treatment distance traveled normalized to the habituation performance.

Sensorimotor Gating
Sensorimotor gating (i.e. pre-pulse inhibition of startle response)
was assessed as previously published (Karl et al., 2011). Briefly,
one week before testing, mice (n = 8/group) were allowed 30 min
habituation to the prepulse inhibition (PPI) chambers at background noise levels (70 dB; SR-LAB; San Diego Instruments).
Animals received an i.p. injection of NRG1 (5, 25, or 50 µg/kg),
PCP (3 mg/kg), PCP + NRG1 (5, 25, or 50 µg/kg), or vehicle directly
following a 5 min re-acclimatization period in the PPI chambers.
Sensorimotor gating was tested in 100 trials over 25 min, consisting of 3 startle response blocks and PPI response trails (prepulse intensities: 74 dB, 82 dB, and 86 dB),

Microdialysis and Amino Acid Quantification
Microdialysis was performed as described previously (Landgraf
et al., 2003). Briefly, similar to the i.c.v. cannula implantation, a
microdialysis guide cannula (MAB 6.14.IC Microbiotech/SE) was
surgically implanted into either the medial PFC or dorsal CA1
to accommodate a microdialysis probe. Mice were individually
housed in purpose-built microdialysis cages (25 x 25 x 40 cm,
grey Polyvinyl chloride (PVC) with clear front) for all experimental procedures, which allowed free access to food and water. After
seven days of recovery, the microdialysis probe (1 mm membrane
length, 15 kDa cut off, MAB 6.14.1, Microbiotech) was inserted into
the guide cannula and lowered into the respective target area
of the right mPFC/dCA1 2.5 h before the first treatment. It was
connected via low volume in- and outflow tubing (FEP-tubing,
4001004, Microbiotech; fluid swivel 375/D/22QM, Instechlabs) via a
counter-balanced lever arm to a syringe pump (1 µl/min, Harvard
Instruments). Microdialysis samples were collected in 10 min
intervals 2.5 h after probe insertion. Animals received 10 min infusions with NRG1 (10 nM), PCP (10 µM), and NRG1 + PCP, separated
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by 2.5 h of ACSF each. Potassium-stimulated neurotransmitter
release (Stanford et al., 2000) and probe placement were confirmed before data analysis.

Gas Chromatography Mass Spectrometry Sample
Processing and Analysis
Derivatization followed a previously published method (Eckstein
et al., 2008). Briefly, samples were supplemented with heavy isotopes (20 pmole GABA-d6, 200 pmole Glycine-C13-2, N15, 2 pmole
Glutamate-d5) and diluted in acetonitrile/methanol (1:1) before
centrifugation. The supernatant was dried off at 37°C under
nitrogen before derivatization with pentafluoropropionic acetic
anhydride and 2,2,3,3,3-pentafluoro-1-propanol (PM Separations
PTY). Following derivatization, samples were resuspended in toluene for analysis. Samples were analyzed using negative chemical ionization in a gas chromatograph with triple quad mass
spectrometry (GC-MS/MS, 7000B & 7890A, Agilent Technologies).
Specific multiple-reaction monitoring transitions were performed to monitor the glutamate ion transition m/z 379.0 →
m/z 188.0, qualifier transitions (m/z 537.0 → m/z 313.0 and m/z
537.0 → m/z 217.0), and m/z 542 → m/z 221 for the corresponding isotopic d5 labeled internal standard. GABA ion transition was
detected at m/z 191.1 → 109.0, qualifier transitions (m/z 321.0 →
m/z 301.0 and m/z 341.0 → m/z 208.0), and m/z 327 → m/z 306 for
the corresponding isotopic d6 labeled internal standard. Glycine
ion transition was detected at m/z 333.0 → m/z 313.0, qualifier
transitions at m/z 333.0 → 200.0 and m/z 365.0 → 232.0, and m/z
336.0 → m/z 316.0 for the corresponding isotopic C13-2 labeled
internal standard. The area under the curve for peaks of GABA,
glutamate, and glycine were normalized by their respective internal standard peaks, followed by normalization to the relevant
baseline samples.

Statistical Analysis
Pre- and post-injection locomotor activity and startle following
pulse-only trails were assessed by a one-way analysis of variance (ANOVA), followed by a Bonferroni’s multiple comparison
post hoc analysis when required. Single time point differences in
distance traveled were assessed by one-way ANOVA for repeated
measurements, followed by Bonferroni’s multiple comparison
post hoc analysis. Differences in PPI were assessed using twoway repeated-measures ANOVA (treatment x pre-pulse intensity),
followed by Bonferroni’s multiple comparison post hoc analysis.
Treatment effects on neurotransmitter levels were assessed
using Linear Mixed Model (LMM) on repeated measurements for
each brain area and transmitter following baseline normalization. Overall differences in extracellular neurotransmitter levels
were assessed by calculating the area under the curve (AUC) for
the entire sampling period using the trapezoidal rule. AUC and
single time point differences were assessed by one-way ANOVA
for repeated measurements, followed by Tukey’s post hoc analysis where appropriate. Analyses were performed using SPSS 19.0
(IBM). Statistical significance was accepted at p < 0.05 and data are
presented as the mean ± standard error of the mean.

Results
NRG1 Treatment Does Not Alter Locomotor Activity,
But Prevents PCP-Induced Hyperlocomotion
Increased spontaneous locomotor activity in the open field
arena is considered to be an indirect measure of hyperdopaminergic and hypoglutamateric tone experienced by patients with

4

|

International Journal of Neuropsychopharmacology, 2015

schizophrenia during a psychotic episode (Adell et al., 2012) and
reported from several NRG1 genetic animal models (Lu et al., 2011).
Locomotor activity differed significantly between treatment
groups (F7, 54 = 7.35, p < 0.001), with activity of i.p. NRG1-treated
mice being similar to vehicle-treated mice (5 µg/kg: p = 0.22,
25 µg/kg and 50 µg/kg: p = 0.99 vs vehicle; Figure 1A). Mice treated
with PCP showed an increase in locomotor activity (p = 0.003 vs
vehicle; Figure 1A), consistent with previous studies (Gleason
and Shannon, 1997; Mouri et al., 2011). Combining PCP with NRG1
i.p. altered the PCP-induced increase in locomotor activity in a
concentration-dependent manner. NRG1 at 25 μg/kg, but not at 5
or 50 µg/kg, prevented the PCP hyperlocomotive effect (p = 0.02 vs
PCP, 5 μg/kg: p = 0.99, 50 μg/kg: p = 0.79 vs PCP; Figure 1A).
One-way ANOVA also revealed a significant treatment effect
on locomotor activity of i.c.v. treated mice (F6, 43 = 6.6, p < 0.001).
Locomotor activity following i.c.v. NRG1 treatment was similar
to vehicle-treated animals (p = 0.99 for 30 ng/kg and 300 ng/kg
vs vehicle; Figure 1B). PCP treatment again increased locomotor
activity (p < 0.001 vs vehicle; Figure 1B). Similar to i.p. treatment,
NRG1 i.c.v. altered the PCP effect in a concentration-dependent
manner. NRG1 at 30 ng/kg, but not at 3 or 300 ng/kg, prevented
PCP-induced hyperlocomotion (p = 0.024 vs PCP; 3 ng/kg and
300 ng/kg: p = 0.99 vs PCP; Figure 1B).
Comparing the distance traveled for each post-treatment interval via repeated-measure two-way ANOVA (i.p.
NRG1 Treatment F3, 28 = 2.93, p = 0.05; i.c.v. NRG1 Treatment F3,
= 8.88, p < 0.001) showed that PCP treatment triggered hyper28
locomotion within 10 min post-treatment (p = 0.002 vs vehicle,
Figure 1C and D). Combined treatment with either i.p. 25 μg/kg
NRG1 (Figure 1C) or i.c.v. 30 ng/kg NRG1 (Figure 1D) prevented
the increase in locomotor activity from the treatment onset
(Figure 1C and D), while NRG1 treatment in the absence of PCP
did not alter locomotor activity.

NRG1 Treatment Prevents PCP-Induced Deficit of
Pre-Pulse Inhibition of Startle
Patients with schizophrenia show impaired sensorimotor gating (Braff et al., 2001), which can be tested in rodents through
inhibition of startle response experiments (Geyer et al., 2001).
In our sensorimotor gating experiment, startle response to
a 120 dB pulse was not affected by any of the treatments (F7,
= 1.5, p = 0.18; Figure 2A). Pre-pulse intensity had a significant
58
effect on PPI for vehicle-treated animals (F1.2, 8.5 = 69.52, p < 0.001;
Figure 2B). Furthermore, PPI differed significantly between treatment groups (F6, 45 = 5.55, p < 0.001). NRG1 treatment at 25 μg/kg
and 50 μg/kg had no effect on PPI performance (p > 0.8 vs vehicle), while 5 µg/kg NRG1 impaired the PPI effect at 74 and 82 dB
pre-pulse intensity (p = 0.01 and p = 0.03 vs vehicle, respectively;
Figure 2B). PCP treatment impaired PPI for all three pre-pulse
intensities (74 dB: p = 0.01, 82 dB: p < 0.001, and 86 dB: p = 0.002
vs vehicle; Figure 2B), which is consistent with previous studies
(Bakshi and Geyer, 1995; Yee et al., 2004). NRG1 prevented the
PCP-induced disruption of PPI for pre-pulses of 82 and 86 dB in
a dose-dependent manner (25 µg/kg NRG1 at 82 dB: p = 0.006;
at 86 dB: p = 0.04; 50 µg/kg NRG1 at 82 dB: p = 0.02; Figure 2B).
The ability of NRG1 to prevent PCP-induced sensorimotor gating impairment indicates an acute influence over several schizophrenia-relevant neurotransmitter systems.

NRG1 Reduces Glutamate and Glycine Levels in the
Mouse PFC In Vivo
The microdialysis experiment was designed to assess the
consequence of increased NRG1 signaling on schizophreniarelevant neurotransmission under healthy and impaired conditions. We first measured GABA, glutamate, and glycine levels in

Figure 1. Peripheral and central administered neuregulin 1 (NRG1) prevents PCP-induced hyperlocomotion in mice. (A & B) Post-treatment distance moved as percentage of habituation locomotion for varying doses of i.p. NRG1 (A, µg/kg) or i.c.v. NRG1 (B, ng/kg), administered in combination with PCP (3 mg/kg) or vehicle (A, 0.9% NaCl;
B, artificial cerebrospinal fluid + 0.9% NaCl). Data is presented as mean percentage difference to habituation locomotion + standard error of the mean (n = 8/group). (C &
D) Mean distance moved within 5 min windows pre- and post-treatment ± standard error of the mean (n = 8/group) after (C, i.p.) vehicle, NRG1 (25 μg/kg), PCP, or NRG1
+ PCP (25 μg/kg + 3 mg/kg); (D, i.c.v. + i.p.) vehicle, NRG1 (30 ng/kg + 0.9% NaCl), PCP (artificial cerebrospinal fluid + 3 mg/kg), or NRG1 + PCP (30 ng/kg + 3 mg/kg). *p < 0.05,
**p < 0.01 vs PCP; #p < 0.01, ##p < 0.001, ###p < 0.0001 vs vehicle.
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Figure 2. Peripheral neuregulin 1 (NRG1) injection prevents PCP-induced prepulse inhibition (PPI) impairment. Mice (n = 7–8/group) treated intraperitoneally
with vehicle, NRG1 (5, 25, or 50 μg/kg), PCP (3 mg/kg), or NRG1 + PCP (5, 25, or
50 μg/kg NRG1 + 3 mg/kg PCP). (A) Treatments had no effect on startle response
to 120 dB pulses (one-way analysis of variance, F7, 58 = 1.502, p = 0.18). Values are
presented as mean of startle intensity + standard error of the mean. (B) Treatment effect on PPI following different prepulse intensities. Values are presented
as mean percentage of PPI + standard error of the mean. #p < 0.05, ##p < 0.01,
###p < 0.001 vs vehicle (veh); *p < 0.05, **p < 0.01 vs PCP.

the PFC following NRG1 retrodialysis and combined with PCP.
The retrodialysis treatments had a significant overall effect on
extracellular glutamate and glycine levels (LMM: glutamate:
F3, 145.8 = 11.41, p < 0.001; glycine: F3, 145.1 = 6.85, p < 0.001), without affecting overall GABA levels (GABA: F3, 123.9 = 0.55, p = 0.64).
By comparing single time point GABA levels, we identified an
increase 10 min after NRG1 treatment (194.0 ± 47.0% of baseline,
p = 0.03; Figure 3A), which returned to baseline levels for the
remaining sampling period. PCP infusion reduced extracellular GABA levels 20 min after treatment (37.6 ± 8.0% of baseline,
p = 0.005; Figure 3A). Combined infusion of NRG1 + PCP prevented this reduction of extracellular GABA levels (104.2 ± 45%,
p > 0.99 vs baseline; Figure 3A). GABA levels expressed as AUC
revealed that none of the three treatments affected overall
GABA concentration across the sampling period (F3, 18.6 = 0.9,
p = 0.46; Figure 3B).
NRG1 infusion reduced extracellular glutamate levels in the
PFC throughout the sampling period (LMM: 50.8 ± 10.2% of baseline, p < 0.001; AUC: 52.2 ± 9.8% of baseline, p = 0.005; Figure 3C
and D). However, neither PCP nor NRG1 + PCP affected glutamate
levels at single time points or during the entire sampling period
(LMM: p = 0.69 and p > 0.99 vs baseline, AUC: p = 0.81 and p = 0.65

Figure 3. Neuregulin 1 (NRG1) reduces extracellular glutamate and glycine in
the prefrontal cortex (PFC) in vivo. Mice (n = 8–10/treatment) received a local
infusion of NRG1 (10 nM), PCP (10 µM), or NRG1 + PCP for 10 min in the PFC by
retrodialysis. Extracellular GABA (A & B), glutamate (C & D), and glycine (E & F)
levels are expressed as a percentage of the respective mean baseline value ±
standard error of the mean for each time point (A, C, E) or baseline equivalent
for area under the curve analysis (B, D, F). Dotted lines indicate baseline levels
before each treatment. *p < 0.05 NRG1 + PCP vs baseline; #p < 0.05 PCP vs baseline;
+
p < 0.05, ++p < 0.01 NRG1 vs baseline.

vs baseline, respectively; Figure 3C and D). Overall, extracellular glycine levels were reduced following NRG1 infusion (AUC:
57.5 ± 9.8% of baseline, p = 0.008; Figure 3E and F). Glycine levels
were not affected by PCP (AUC: p = 0.98 vs baseline). Combined
NRG1 + PCP treatment led to a marked increase in glycine levels during the infusion period (219.0 ± 61.0% of baseline, p = 0.02;
Figure 3E). This increase did not persist for the remaining sampling period (AUC: 125.1 ± 10.4% of baseline, p = 0.11). The PFC
microdialysis experiment shows that NRG1 has an immediate
influence on extracellular neurotransmitter levels with potential relevance to schizophrenia.
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NRG1 Reduces Glutamate and Glycine Levels
and Prevents PCP-Induced GABA Increase in the
Hippocampus In Vivo
Impaired signaling between the hippocampus and PFC has been
implicated in the pathophysiology of schizophrenia (Godsil
et al., 2013). We therefore further investigated the effect of NRG1
increase on hippocampal neurotransmitter levels. In the dorsal CA1 of the hippocampus, the retrodialysis treatments had a
significant effect on overall extracellular glutamate and glycine
levels (glutamate: F3, 158.9 = 16.85, p < 0.001; glycine: F3, 159.1 = 6.68,
p < 0.001), but only affected GABA levels at single time points
(F3, 147.4 = 1.39, p = 0.248). NRG1 showed a tendency to increase
GABA levels during the infusion period (212.0 ± 66.0% of baseline,
p = 0.1), with post-infusion samples remaining close to baseline (Figure 4A). PCP significantly increased extracellular GABA
concentration during the 10 min infusion period (313.0 ± 82.8%
of baseline, p = 0.01; Figure 4A). Co-infusion of NRG1 prevented
the PCP effect (103.0 ± 16.0% of baseline, p = 0.96; Figure 4A). AUC
analysis showed a trend in overall treatment effect on GABA levels (F3,19.9 = 2.8, p = 0.07), with a trend towards reduced overall
GABA levels following NRG1 + PCP (NRG1: p = 0.31; PCP: p > 0.99;
NRG1 + PCP: p = 0.07 vs baseline; Figure 4B).
Glutamate levels were reduced 10 min after NRG1 treatment
for 20 min (10 min: 54.9 ± 8.9% of baseline, p = 0.006; 20 min:
61.7 ± 7.9%, p < 0.007; 30 min: 37.7 ± 4.3%, p < 0.001; Figure 4C).
PCP increased extracellular glutamate levels 20 min after treatment (135.3 ± 10.8% of baseline, p = 0.06; Figure 4C). Combined
treatment of NRG1 + PCP reduced glutamate levels during the
infusion period (28.0 ± 9.0% of baseline, p < 0.001), with levels remaining below baseline until 50 min after treatment
(Figure 4C). The combined treatment therefore prevented the
20 min PCP peak (70.0 ± 10.2% of baseline, p < 0.001 vs PCP). The
AUC analysis (F 3, 23.2 = 5.92, p = 0.004) confirmed this observation,
with NRG1 and NRG1 + PCP leading to glutamate levels below
baseline values (64.3 ± 9.2%, p = 0.07 and 53.2 ± 12.6%, p = 0.01 vs
baseline, respectively; Figure 4D).
Hippocampal glycine levels were unaffected by NRG1 infusion throughout the sampling period (LMM: p = 0.17; Figure 4E).
PCP infusion caused an increase in extracellular glycine levels 50 min after treatment (186.5 ± 47.0% of baseline, p < 0.05;
Figure 4E). However, combined infusion of NRG1 + PCP increased
glycine levels during the infusion period (196.0 ± 58.0% of baseline, p = 0.047, Figure 4E). None of the treatments affected overall
glycine levels compared to baseline (Figure 4F).

Discussion
In the present study, we showed that NRG1 treatment: (1) did not
affect spontaneous behavior, but prevented PCP-induced behavioral impairments in the open field and prepulse inhibition paradigms; (2) reduced extracellular glutamate and glycine levels
in the PFC and hippocampus; and (3) prevented PCP-induced
changes to extracellular GABA levels in the hippocampus. With
these results we provide the first compelling in vivo evidence for
the involvement of NRG1 in schizophrenia-relevant behavior
and neurotransmission and its treatment potential.

NRG1 Treatment Does Not Affect Spontaneous
Behavior, But Prevents PCP-Induced Impairments
NRG1 administration did not adversely affect performance
in the behavioral paradigms tested. Mice receiving central
or peripheral NRG1 injections traveled a similar distance as

Figure 4. Neuregulin 1 (NRG1) prevents PCP-induced increase in GABA levels
and reduces extracellular glutamate in the presence of PCP in the dorsal hippocampus CA1 (dCA1) in vivo. Mice (n = 8–10/treatment) received a local infusion
of NRG1 (10 nM), PCP (10 µM), or NRG1 + PCP for 10 min in the dCA1 by retrodialysis. Extracellular GABA (A & B), glutamate (C & D), and glycine (E & F) levels are
expressed as a percentage of the respective mean baseline value ± standard error
of the mean for each time point (A, C, E) or baseline equivalent for area under the
curve analysis (B, D, F). Dotted lines indicate baseline levels before each treatment. T*p = 0.07, *p < 0.05, **p < 0.001 NRG1 + PCP vs baseline; T#p = 0.06, #p < 0.05,
##
p < 0.01 PCP vs baseline; T+p = 0.07, +p < 0.05, ++p < 0.001 NRG1 vs baseline.

vehicle-treated mice, and no difference in spontaneous behavior was observed. This finding is in line with a published study
which reports no difference in locomotor activity 24 h and
28 d after two days of subcutaneous NRG1 (166 µg/kg) treatment
in mice (Mahar et al., 2011). Experiments with genetic animals
have shown that reduced NRG1 (e.g. reducing ERBB or NRG1
expression) or increased NRG1 signaling (e.g. overexpression of
NRG1 type I) leads to hyperactivity in the open field arena (Karl
et al., 2007; Kato et al., 2010; Wen et al., 2010; Luo et al., 2013;
Yin et al., 2013). While acute application of NRG1 had no effect
on locomotion, chronically altering the NRG1 signaling pathway
likely caused the locomotor differences in genetically-modified
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animals, instead of short-term effects of NRG1 on related
neurotransmission.
Several NRG1 transgenic animal models show sensorimotor
gating impairments (Chen et al., 2008; Deakin et al., 2009; Wen
et al., 2010; Karl et al., 2011). We therefore assessed the acoustic
startle response following NRG1 treatment in wild type mice.
Neither startle response nor PPI performance was affected by
25 or 50 μg/kg NRG1 compared to vehicle, while 5 μg/kg reduced
the PPI effect. These results suggest that sensorimotor gating
differences caused by genetically modifying the NRG1 signaling
pathway are not related to acute NRG1 signaling. Furthermore,
the dose-dependent behavioral response indicates that minor
imbalances in NRG1 signaling potentially contribute to the disorder phenotype.
To explore the consequence of increased NRG1 signaling on
schizophrenia-relevant behavioral impairments, we administered NRG1 to mice also receiving PCP. Consistent with previous publications, PCP treatment induced hyperlocomotion and
impaired PPI (Bakshi and Geyer, 1995; Gleason and Shannon,
1997; Mouri et al., 2011). We subsequently discovered that NRG1
treatment dose-dependently prevented the PCP-induced hyperlocomotion and PPI impairment (Figures 1 and 2B). The PCProdent model is commonly used for identifying substances with
antipsychotic-like potential (Adell et al., 2012). Current antipsychotics, including olanzapine, clozapine, and haloperidol, have
been shown to prevent PCP-induced hyperlocomotion and PPI
impairments (Bakshi and Geyer, 1995; Gleason and Shannon,
1997; Geyer et al., 2001; Linn et al., 2003; Mutlu et al., 2011). By
preventing PCP-induced behavior impairments, NRG1 treatment
shows antipsychotic-like potential. Remarkably, NRG1 i.c.v. and
i.p. administrations had comparable outcomes against PCPinduced hyperlocomotion, which suggests that peripheral NRG1
administration has neuromodulatory properties on central
receptors. This observation supports previous studies, which
have shown that peripherally-administered recombinant NRG1
can readily cross the blood-brain barrier (Kastin et al., 2004; Kato
et al., 2011; Rösler et al., 2011).

NRG1 Reduces Glutamate and Glycine Levels and
Prevents PCP-Induced GABA Increase In Vivo
In the brain, the NRG1 receptor ERBB4 is predominantly located
on GABAergic interneurons, with high expression in the PFC and
hippocampus (Fazzari et al., 2010; Neddens et al., 2011), which
are associated with the behavioral symptoms of schizophrenia
(Inan et al., 2013). This expression pattern, together with the
reported effects of NRG1 on neurotransmission in vitro, suggests that NRG1 signaling may influence GABAergic and glutamatergic neurotransmission in the PFC and hippocampus.
We therefore assessed the effects of local NRG1 application on
extracellular GABA, glutamate, and glycine levels in the PFC and
hippocampus in vivo. Glutamate and glycine levels in both brain
regions were reduced following NRG1 retrodialysis (Figure 3B
and C and Figure 4B and C). This effect potentially contributes to
the reported reduction in NMDA receptor currents and subunit
internalization following NRG1 application in PFC slice preparations (Gu et al., 2005). While recent work shows that NRG1 can
reduce glutamate release via the pre-synaptic LIMK1 protein
(Yin et al., 2013), the exact mechanism underlying the present
finding is worthy of further investigation.
NRG1 application in vitro has been shown to increase depolarization-evoked GABA release in the PFC by activating ERBB4
receptors (Woo et al., 2007; Wen et al., 2010). Prolonged NRG1
treatment has been shown to reduce surface levels of GABA-A
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receptors (Okada and Corfas, 2004), potentially compensating for the reported increase in GABA release. We observed an
increase in GABA levels during the infusion period in the hippocampus and, slightly delayed, in the PFC. Our in vivo findings
suggest that GABA-releasing cells in the adult nervous system
respond to acute NRG1 signaling, adding support to the existing
in vitro studies.
Deficits in the GABAergic and glutamatergic system have
been identified in the PFCs and hippocampi of patients with
schizophrenia (Gonzalez-Burgos et al., 2011; Nakazawa et al.,
2012). We therefore investigated whether the response to NRG1
administration would differ when combined with PCP. PCP treatment caused a short-term increase in GABA levels in the hippocampus. While reduced GABA levels in the PFCs of rodents
following PCP infusion have been reported previously (Yonezawa
et al., 1998; Zhu et al., 2004), these studies used higher PCP concentrations (10 vs 50 and 100 μM) coupled with longer treatment durations (10 vs 40 min), which are likely responsible for
the effect difference. Combined NRG1 and PCP infusion completely prevented the PCP-induced increase in GABA levels. The
observed effect on GABA by combined NRG1 and PCP treatment
occurred during the retrodialysis period, suggesting a direct
action on local neurotransmitter release or uptake mechanisms.
Notably, a recent study identified an interaction between ERBB4
and GABA-A receptors in hippocampal interneurons, which
possibly contributed to the observed NRG1 treatment effect
(Mitchell et al., 2013).
In line with existing reports (Zhu et al., 2004), local PCP infusion in the PFC and hippocampus did not change glutamate or
glycine levels. However, glycine levels were markedly increased
during the infusion period of NRG1 and PCP in both brain
regions, while glutamate levels remained below baseline levels
for the sampling period. Since the effect duration differs for both
neurotransmitters, separate mechanisms are likely involved.
Furthermore, there appears to be no correlation between the
treatment effects on the extracellular levels of GABA, glutamate,
and glycine. PCP and NRG1 have been reported to alter extracellular dopamine levels in vivo (Yonezawa et al., 1998; Zhu et al.,
2004; Kwon et al., 2008). Assessing the effect of the combined
treatment on dopamine levels will aid the understanding of
mechanisms underlying the effect of NRG1 administration by
itself and in the presence of PCP on neurotransmission.
The effect of antipsychotics on local PCP-induced neurotransmitter alterations has not been published. However, local
clozapine and haloperidol administration have been reported
to reduce GABA levels, with clozapine, but not haloperidol, also
increasing glutamate levels in the PFCs of rats (Bourdelais and
Deutch, 1994; López-Gil et al., 2007). NRG1 infusion changed
GABA, glutamate, and glycine levels in the presence of PCP, indicating a potential for NRG1 signaling to acutely alter impaired
neurotransmission.

The Potential Implications of Altered NRG1 Signaling
in Schizophrenia
Existing in vitro experiments have indicated that NRG1 administration is more likely to affect neurotransmitter receptor availability than neurotransmitter release in PFC and hippocampus
slice preparations (Liu et al., 2001; Okada and Corfas, 2004; Chang
and Fischbach, 2006; Pitcher et al., 2011; Shamir et al., 2012). The
observed rapid neurotransmitter level changes following NRG1
and the combined NRG1 and PCP infusion are therefore noteworthy. However, since each sample covers a 10 min window,
we cannot determine the exact order of neurochemical events,
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which is of particular relevance since GABA and glycine have
been reported to influence glutamate levels (Tanaka et al., 2003;
Lee et al., 2009). Furthermore, the behavioral response to i.c.v.
NRG1 suggests that neurotransmission in other brain regions,
such as the striatum, are also rapidly affected.
The effects of NRG1-ERBB4 signaling have been suggested to
follow an “inverted-U model” when studying neuronal activity
(Role and Talmage, 2007). The dose-dependent response of NRG1
against PCP-induced behavioral impairments indicates a nonlinear concentration response. U-shaped behavioral responses
have been associated with PFC dopamine levels (Husain and
Mehta, 2011), and are considered critical for the development
of pharmacological agents targeting cognitive symptoms of
schizophrenia (Millan et al., 2012). However, the bi-phasic doseresponse of NRG1 in the present study requires further exploration using a wider concentration range to determine the exact
NRG1-ERBB complex relationship. Broadening the concentration
spectrum may also shed light on the consequence of altered
NRG1 signaling in humans, since both increased and decreased
NRG1 expression has been observed in patients with schizophrenia (Deng et al., 2013). Furthermore, chronically increased
or decreased NRG1 signaling in mice has led to behavioral and
structural differences (Lu et al., 2011). This highlights the need
to assess the NRG1 signaling system at different stages during development. Such investigations will also provide critical
information about the onset and duration of a possible NRG1
treatment strategy following our identification of the antipsychotic-like treatment potential. The suitability of NRG1 administration to humans has recently been explored in successful
phase II clinical trials in patients with chronic heart failure (Gao
et al., 2010; Jabbour et al., 2011). Thus, a combination of preclinical and clinical data suggests that NRG1 has a therapeutic
system-dependent effect, likely within a specific concentration
range.

Conclusion
In the present study, we showed that acute treatment with
NRG1 has little effect on spontaneous behavior, while significantly reducing glutamatergic neurotransmission in the PFC
and hippocampus. Importantly, our results demonstrate that
NRG1 administration prevents schizophrenia-relevant behavior
impairments and disruptions of the GABAergic system caused
by PCP. The ability of NRG1 treatment to alter GABA, glutamate,
and glycine levels in the presence of PCP also suggests that NRG1
signaling has the potential to alter disrupted neurotransmission
in patients with schizophrenia. Our findings are therefore the
first step towards exploring the therapeutic potential of NRG1
for the treatment of schizophrenia.
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